Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Subsidiaries of Astellas and Novartis co-led a series B round that took Harvard's cancer treatment developer's overall funding to $60m.

Pavilion Capital and Hansjörg Wyss featured in a series B round for Harvard-founded ReadCoor, whose existing shareholders also include Lilly Asia Ventures.

Fusion Pharmaceuticals has now raised $171m altogether to deliver cancer radiopharmaceuticals based on McMaster University research.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Jasper Therapeutics, based in part on Stanford research, has raised a $15m series A extension on the back of early clinical results from its blood transplant conditioning program.

Stanford-StartX Fund-backed Inflammatix received series C funding led by Grey Sky ahead of the European release of its acute infection diagnostics platform.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Deep Genomics will use the money to advance drug candidates created through its AI drug development model, based on research by Toronto faculty.

Alexandria Venture Investments has helped UW's genetic sequencing technology developer TwinStand raise series A financing.